Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2006

View Archived Issues

Inhaled insulin delivery systems discussed at the recent EASD meeting

Santhera to develop SNT-MC17 for Leber's hereditary optic neuropathy

Juvaris awarded SBIR grant for AML vaccine development

Axcan and AGI sign license and codevelopment agreement for AGI-010

Crystallographic analysis findings for PRS-010 and PRS-050

Elocalcitol shows no benefit for pelvic pain in phase IIa study

Interim findings for phase IIb study of AeroLEF

Ortho-McNeil extends research term in Arena GDIR partnership

Cellegy to sell assets to Prostrakan

Cumbre and TB Alliance to develop new antituberculosis agents

Meditor advances phase II study of MTR-107 in ESRD patients

Night release prednisone superior to standard regimen for morning RA symptoms

Medivation cleared for phase I/IIa study Dimebon

Orphan drug designation for glufosfamide in pancreatic cancer

New study examines gender differences in HIV treatment

Selective thyroid beta agonist QRX-431 studied in phase I

Axonyx stockholders approve TorreyPines merger

Maribavir begins phase III in transplant patients

Recent patents describe new compounds for hypertension and other cardiovascular diseases

Novel therapeutic agents for respiratory disorders patented

NS5B RNA-dependent RNA polymerase inhibitors reported by Biota

CrystalGenomics updates CG-400549, their preclinical candidate against Staphylococcus aureus

Eprodisate MAA for AA amyloidosis accepted for review

Champix approved in Europe

Approvable letter for Labopharm's once-daily formulation of tramadol

Rituxan approved for two new indications in NHL

Approvable letter for paliperidone ER in schizophrenia

Wf-516: an antidepressant with activity due to 5-HT1A antagonism and 5-HT reuptake inhibition

Binding mechanism to beta-lactamases by bridged monobactam analogues described

Preclinical data on Pfizer's PF-987296 show activity against Gram-positive infections

New potential antiviral compounds against Lassa fever virus developed by SIGA

Protez's novel broad-spectrum carbapenem PZ-601 demonstrates efficacy in vitro and in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.